Vorapaxar in atherosclerotic disease management. - Wikidata - awgldk - TriplyDB

Vorapaxar in atherosclerotic disease management.

Vorapaxar in atherosclerotic disease management.

http://www.wikidata.org/entity/Q38355060

about

Vorapaxar in atherosclerotic disease management.

http://www.wikidata.org/entity/Q38355060

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Vorapaxar in atherosclerotic disease management.

@en

type

label

Vorapaxar in atherosclerotic disease management.

@en

prefLabel

Vorapaxar in atherosclerotic disease management.

@en

P1433

Q38355060-EBAA1704-A9C9-4566-8829-83AA8A276F86

P1476

Q38355060-906D1834-0AB5-4691-B66C-B421FF2430CF

P2093

Q38355060-10E082BD-971C-44FD-AF61-241BEFAC098D

Q38355060-924DE98F-A668-47B9-9624-C48D569933E5

Q38355060-AED37095-5AF0-41A2-BA52-89CBC41A80F9

Q38355060-C8A5D843-EFBB-47F2-81B6-DDD3B183DB53

Q38355060-CCC2DE5C-2C8E-45AE-8318-2D84483A832A

P2860

Q38355060-042DAFFD-EF69-4C77-B8A1-4628AD87FB6F

Q38355060-12245948-5B53-4CBB-869C-41F451B3BB95

Q38355060-222AC052-9A12-42E6-9275-6C89ACE3E183

Q38355060-24A92766-5BCF-42A1-8A2B-008300FFC5BA

Q38355060-28B1B1FA-29DA-49C6-A418-01F1E5D7D2D0

Q38355060-393B5F0E-6B9F-4ABD-9E82-914807F8EC80

Q38355060-49559045-D896-4A0B-9914-C825C50B3BD2

Q38355060-506E7326-D500-4EC4-B5C9-475A55CE4881

Q38355060-56DDF364-C297-4E07-9265-4EF67B7BFFA4

Q38355060-571B28B1-5848-4F4B-BCEA-E08BB1A65700

P304

Q38355060-A3B8060B-271C-4CE4-942B-A37E2BF1A471

P31

Q38355060-CCECC04C-DCE3-40B0-9C37-D7DEE3BAA64D

P356

Q38355060-8184F16B-1977-4DD6-AABD-E63C1D48B96E

P407

Q38355060-15A1E228-7263-42E7-93FF-ABA7592B0ABB

P433

Q38355060-3B5A085D-3EFE-4523-8D36-52391600E992

P478

Q38355060-7A639E29-C1EF-4EE8-8303-B08EE8ADB6AE

P577

Q38355060-16AF05F5-2752-4B23-A04C-4B4DE9573C79

P5875

Q38355060-0635EC73-7458-4E4A-BD94-3F9F5F730926

P698

Q38355060-08416567-C15A-46AC-ABBA-EA9EF0F93B7E

P921

Q38355060-C5868F5D-067D-4B40-B008-767AB0CA9FF7

P356

1060028015571410

P1433

Annals of Pharmacotherapy

P1476

Vorapaxar in atherosclerotic disease management.

@en

P2093

Jean M Nappi

http://www.w3.org/2001/XMLSchema#string

Judy W M Cheng

http://www.w3.org/2001/XMLSchema#string

Patricia A Howard

http://www.w3.org/2001/XMLSchema#string

Sarah A Spinler

http://www.w3.org/2001/XMLSchema#string

Vincent Colucci

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

Heart disease and stroke statistics--2014 update: a report from the American Heart Association

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Vorapaxar in the secondary prevention of atherothrombotic events.

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects.

P304

599-606

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028015571410

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272295898

http://www.w3.org/2001/XMLSchema#string

P698

25680760

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis